A recent retrospective study found that nearly 18% of patients diagnosed with multiple sclerosis (MS) before being referred to a medical center for treatment were actually misdiagnosed.
A recent retrospective study found that nearly 18% of patients diagnosed with multiple sclerosis (MS) before being referred to a medical center for treatment were actually misdiagnosed.
Misdiagnosis can have a significant impact on patient morbidity and healthcare costs. Researchers analyzed the cases of 241 patients who had been diagnosed and then referred to 2 medical centers for treatment over the course of 1 year. The study authors looked to identify how many patients were misdiagnosed and if they shared any common characteristics.
Overall, the authors found that many patients who came to the medical centers with an MS diagnosis did not fulfill the criteria for that determination. On average, patients spent 4 years being treated for MS before receiving a correct diagnosis.
“The diagnosis of MS is tricky. Both the symptoms and [magnetic resonance imaging] testing results can look like other conditions, such as stroke, migraines, and vitamin B12 deficiency. You have to rule out any other diagnoses, and it’s not perfect science,” Marwa Kaisey, MD, a neurologist at Cedars-Sinai, said in a statement.
Among those misdiagnosed, 72% had been prescribed MS treatments. Of these patients, 48% received therapies that carry a known risk of developing progressive multifocal leukoencephalopathy. Conversely, the most common correct diagnosis was migraine, followed by radiologically isolated syndrome, spondylopathy, and neuropathy.
“I’ve seen patients suffering side effects from the medication they were taking for a disease they didn’t have,” said Kaisey. “Meanwhile, they weren’t getting treatment for what they did have. The cost to the patient is huge— medically, psychologically, financially.”
In this study alone, the investigators estimated that the unnecessary treatments cost almost $10 million. The authors hope that the results from the study will lead to better availability of treatment for patients who do have the disease.
Reference
Kaisey M, Solomon A, Luu M, Giesser B, Sicotte N. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers [published February 1, 2019]. Mult Scler Relat Disord. doi.org/10.1016/j.msard.2019.01.048
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS
March 11th 2024The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
Read More
Choroid Plexus Indicated in MS Pathology
February 9th 2024A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Read More